174 related articles for article (PubMed ID: 35334353)
1. Verbal learning and memory in youth with neurofibromatosis type 1 and plexiform neurofibromas: Relationships with disease severity.
Loucas C; Wolters P; Toledo-Tamula MA; Rhodes A; Baldwin A; Goodwin A; Widemann B; Martin S
Eur J Paediatr Neurol; 2022 May; 38():7-12. PubMed ID: 35334353
[TBL] [Abstract][Full Text] [Related]
2. Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social-emotional functioning, and quality of life.
Wolters PL; Burns KM; Martin S; Baldwin A; Dombi E; Toledo-Tamula MA; Dudley WN; Gillespie A; Widemann BC
Am J Med Genet A; 2015 Sep; 167A(9):2103-13. PubMed ID: 25976979
[TBL] [Abstract][Full Text] [Related]
3. Predictors of cognitive development in children with neurofibromatosis type 1 and plexiform neurofibromas.
Hou Y; Allen T; Wolters PL; Toledo-Tamula MA; Martin S; Baldwin A; Reda S; Gillespie A; Goodwin A; Widemann BC
Dev Med Child Neurol; 2020 Aug; 62(8):977-984. PubMed ID: 32052421
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal association between executive function and academic achievement in children with neurofibromatosis type 1 and plexiform neurofibromas.
Hou Y; Wu X; Allen T; Toledo-Tamula MA; Martin S; Gillespie A; Goodwin A; Widemann BC; Wolters PL
J Int Neuropsychol Soc; 2023 Nov; 29(9):839-849. PubMed ID: 36750981
[TBL] [Abstract][Full Text] [Related]
5. Social-emotional functioning of children and adolescents with neurofibromatosis type 1 and plexiform neurofibromas: relationships with cognitive, disease, and environmental variables.
Martin S; Wolters P; Baldwin A; Gillespie A; Dombi E; Walker K; Widemann B
J Pediatr Psychol; 2012 Aug; 37(7):713-24. PubMed ID: 22353803
[TBL] [Abstract][Full Text] [Related]
6. Neuropsychological profile in adults with neurofibromatosis type 1 compared to a control group.
Descheemaeker MJ; Plasschaert E; Frijns JP; Legius E
J Intellect Disabil Res; 2013 Sep; 57(9):874-86. PubMed ID: 23095048
[TBL] [Abstract][Full Text] [Related]
7. Clinical features and disease severity in patients with mosaic neurofibromatosis type 1: a single-center study and literature review.
Ejerskov C; Raundahl M; Gregersen PA; Handrup MM
Orphanet J Rare Dis; 2021 Apr; 16(1):180. PubMed ID: 33853649
[TBL] [Abstract][Full Text] [Related]
8. Audiometric and Otologic Findings in Children and Young Adults with Neurofibromatosis Type 1 and Plexiform Neurofibromas.
Idowu V; Christensen J; Gross AM; Dombi E; Miles JR; King K; Chisholm J; Zalewski C; Baldwin A; Whitcomb P; Burgess C; Widemann BC; Brewer CC; Kim HJ
Laryngoscope; 2023 Oct; 133(10):2770-2778. PubMed ID: 36583617
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas.
Kim A; Gillespie A; Dombi E; Goodwin A; Goodspeed W; Fox E; Balis FM; Widemann BC
Neurology; 2009 Oct; 73(16):1273-9. PubMed ID: 19841379
[TBL] [Abstract][Full Text] [Related]
10. Clinic-based study of plexiform neurofibromas in neurofibromatosis 1.
Waggoner DJ; Towbin J; Gottesman G; Gutmann DH
Am J Med Genet; 2000 May; 92(2):132-5. PubMed ID: 10797438
[TBL] [Abstract][Full Text] [Related]
11. Adolescents and young adults with neurofibromatosis type 1: A descriptive study of adaptive functioning.
Struemph KL; Watts ATM; Wolters PL; Tamula MA; Baldwin A; Widemann B; Martin S
Am J Med Genet A; 2022 Feb; 188(2):488-497. PubMed ID: 34731530
[TBL] [Abstract][Full Text] [Related]
12. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.
Robertson KA; Nalepa G; Yang FC; Bowers DC; Ho CY; Hutchins GD; Croop JM; Vik TA; Denne SC; Parada LF; Hingtgen CM; Walsh LE; Yu M; Pradhan KR; Edwards-Brown MK; Cohen MD; Fletcher JW; Travers JB; Staser KW; Lee MW; Sherman MR; Davis CJ; Miller LC; Ingram DA; Clapp DW
Lancet Oncol; 2012 Dec; 13(12):1218-24. PubMed ID: 23099009
[TBL] [Abstract][Full Text] [Related]
13. Patient Reported Outcomes Measurement Information System and Quality of Life in Neurological Disorders Measurement System to Evaluate Quality of Life for Children and Adolescents with Neurofibromatosis Type 1 Associated Plexiform Neurofibroma.
Lai JS; Jensen SE; Charrow J; Listernick R
J Pediatr; 2019 Mar; 206():190-196. PubMed ID: 30413310
[TBL] [Abstract][Full Text] [Related]
14. Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study.
Weiss B; Widemann BC; Wolters P; Dombi E; Vinks AA; Cantor A; Korf B; Perentesis J; Gutmann DH; Schorry E; Packer R; Fisher MJ
Pediatr Blood Cancer; 2014 Jun; 61(6):982-6. PubMed ID: 24851266
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal study of neurofibromatosis 1 associated plexiform neurofibromas.
Tucker T; Friedman JM; Friedrich RE; Wenzel R; Fünsterer C; Mautner VF
J Med Genet; 2009 Feb; 46(2):81-5. PubMed ID: 18930997
[TBL] [Abstract][Full Text] [Related]
16. NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors.
Perry A; Roth KA; Banerjee R; Fuller CE; Gutmann DH
Am J Pathol; 2001 Jul; 159(1):57-61. PubMed ID: 11438454
[TBL] [Abstract][Full Text] [Related]
17. High frequencies of plexiform neurofibromas, mental retardation, learning difficulties, and scoliosis in Brazilian patients with neurofibromatosis type 1.
Trovó-Marqui AB; Goloni-Bertollo EM; Valério NI; Pavarino-Bertelli EC; Muniz MP; Teixeira MF; Antonio JR; Tajara EH
Braz J Med Biol Res; 2005 Sep; 38(9):1441-7. PubMed ID: 16138229
[TBL] [Abstract][Full Text] [Related]
18. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas.
Armstrong AE; Belzberg AJ; Crawford JR; Hirbe AC; Wang ZJ
BMC Cancer; 2023 Jun; 23(1):553. PubMed ID: 37328781
[TBL] [Abstract][Full Text] [Related]
19. Neurofibromatosis Type 1 with a Giant Diffuse Plexiform Neurofibroma Invading the Liver.
Yokogawa Y; Suzuki T; Suzuki H; Nemoto R; Shimizu H; Ueda T; Uchihara D; Okubo Y; Ichii O; Tai M; Ejiri Y; Harada M
Intern Med; 2023 Oct; 62(20):2971-2975. PubMed ID: 36792186
[TBL] [Abstract][Full Text] [Related]
20. NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.
Weiss BD; Wolters PL; Plotkin SR; Widemann BC; Tonsgard JH; Blakeley J; Allen JC; Schorry E; Korf B; Robison NJ; Goldman S; Vinks AA; Emoto C; Fukuda T; Robinson CT; Cutter G; Edwards L; Dombi E; Ratner N; Packer R; Fisher MJ
J Clin Oncol; 2021 Mar; 39(7):797-806. PubMed ID: 33507822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
